Exploring how a dietary supplement affects gut fungi in healthy adults
Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot Study
This study is testing if a dietary supplement called L-Phenylalanine can change the types of fungi in the gut of healthy adults.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Weill Medical College of Cornell University Academic / other |
| Locations | 1 site (New York, New York) |
| Trial ID | NCT06433310 on ClinicalTrials.gov |
What this trial studies
This pilot study investigates the impact of the dietary supplement L-Phenylalanine on the production of phenylpropionic acid (PPA) and its effects on the fungal populations in the gut microbiome of healthy volunteers. Participants will receive a 14-day supply of L-Phenylalanine capsules, and the study aims to assess how this supplementation influences the diversity of gut mycobiota. The research focuses on understanding the relationship between PPA levels and changes in fungal populations, which may have implications for gut health. The study is designed to fill gaps in knowledge regarding the functional dynamics of gut microbiota and their metabolites.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy adults over the age of 18 without any gastrointestinal conditions.
Not a fit: Patients with a history of gastrointestinal conditions, recent antibiotic or antifungal use, or allergies to L-Phenylalanine will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new insights into dietary interventions that promote gut health by modulating fungal populations.
How similar studies have performed: While there is existing research on the effects of dietary supplements on gut microbiota, this specific approach focusing on L-Phenylalanine and its antifungal metabolite PPA is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female adults over the age of 18 years Exclusion Criteria: * History of a diagnosis of any gastrointestinal condition, such as inflammatory bowel syndrome or disease * Antibiotic usage within the past two weeks * Antifungal usage within the past month * Allergy to L-Phenylalanine or individuals with phenylketonuria (PKU) * Adults taking medications known to interact with L-phenylalanine supplements, such as Monoamine Oxidase Inhibitors (MOAI), L-DOPA, and some antipsychotic drugs (complete and extensive drug list will be provided to interested participants during screening) * Pregnant or nursing women
Where this trial is running
New York, New York
- Belfer Research Building — New York, New York, United States (Recruiting)
Study contacts
- Principal investigator: Iliyan D Iliev, PhD — Weill Medical College of Cornell University
- Study coordinator: Aurelia Li, MS
- Email: aul4004@med.cornell.edu
- Phone: 732-822-6836
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.